drugset / Trial / NCT05412446
99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes
Phase 2
Completed
30 enrolled
Tomsk National Research Medical Center of the Russian Academy of Sciences
Uppsala University · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
An open-label, single center study with 99mTc-ADAPT6 SPECT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-ADAPT6 SPECT and standard histopathology from relevant tumor and lymph node biopsies.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADAPT6-SPECT | Diagnostic / imaging agent | — | — |